Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

PVI/Seronet team

doi:10.1016/j.ccell.2021.06.014

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

PVI/Seronet team

Research output: Contribution to journal › Letter › peer-review

174 Scopus citations

Original language	English
Pages (from-to)	1028-1030
Number of pages	3
Journal	Cancer Cell
Volume	39
Issue number	8
DOIs	https://doi.org/10.1016/j.ccell.2021.06.014
State	Published - 9 Aug 2021

Keywords

COVID-19
SARS-CoV-2
hematology
multiple myeloma
oncology
vaccine

Access to Document

10.1016/j.ccell.2021.06.014

Cite this

@article{af6d9cf36bb94e3db1d846dd278e7f2c,

title = "Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma",

keywords = "COVID-19, SARS-CoV-2, hematology, multiple myeloma, oncology, vaccine",

author = "{PVI/Seronet team} and {Van Oekelen}, Oliver and Gleason, {Charles R.} and Sarita Agte and Komal Srivastava and Beach, {Katherine F.} and Adolfo Aleman and Katerina Kappes and Radhika Banu and Berm{\'u}dez-Gonz{\'a}lez, {Maria C.} and Chernet, {Rachel L.} and Ferreri, {Emily D.} and Floda, {Daniel L.} and Adolfo Firpo-Betancourt and Giulio Kleiner and Russo, {Kayla T.} and Salimbangon, {Ashley Beathrese T.} and Saksena, {Miti S.} and Shin, {Amber A.} and Julia Matthews and Wanni Mendez and Levy Sominsky and Mulder, {Lubbertus C.F.} and Rao Mendu and Mouhieddine, {Tarek H.} and Bo Wang and Ajai Chari and Carlos Cordon-Cardo and Florian Krammer and Sundar Jagannath and Viviana Simon and Ania Wajnberg and Samir Parekh",

note = "Funding Information: Samir Parekh is supported by the National Cancer Institute (NCI) ( R01 CA244899 , CA252222 ) and receives research funding from Amgen , Bristol Myers Squibb (Celgene), and Karyopharm . This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) (contract 75N93019C00051 ), NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) (contracts HHSN272201400008C and HHSN272201400006C ), and NIAID grants U01AI141990 and U01AI150747 ; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute , National Institutes of Health , under Contract No. 75N91019D00024 , Task Order No. 75N91020F00003 . The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. We would like to thank the study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. We would like to acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai for their help. Funding Information: Samir Parekh is supported by the National Cancer Institute (NCI) (R01 CA244899, CA252222) and receives research funding from Amgen, Bristol Myers Squibb (Celgene), and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) (contract 75N93019C00051), NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) (contracts HHSN272201400008C and HHSN272201400006C), and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. We would like to thank the study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. We would like to acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai for their help. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, and these list Florian Krammer as co-inventor. Viviana Simon and Carlos Cordon-Cardo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports consulting fees for Sanofi Genzyme. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. Other authors report no relevant conflicts of interest. Funding Information: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, and these list Florian Krammer as co-inventor. Viviana Simon and Carlos Cordon-Cardo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports consulting fees for Sanofi Genzyme. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. Other authors report no relevant conflicts of interest. ",

year = "2021",

month = aug,

day = "9",

doi = "10.1016/j.ccell.2021.06.014",

language = "English",

volume = "39",

pages = "1028--1030",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

AU - PVI/Seronet team

AU - Van Oekelen, Oliver

AU - Gleason, Charles R.

AU - Agte, Sarita

AU - Srivastava, Komal

AU - Beach, Katherine F.

AU - Aleman, Adolfo

AU - Kappes, Katerina

AU - Banu, Radhika

AU - Bermúdez-González, Maria C.

AU - Chernet, Rachel L.

AU - Ferreri, Emily D.

AU - Floda, Daniel L.

AU - Firpo-Betancourt, Adolfo

AU - Kleiner, Giulio

AU - Russo, Kayla T.

AU - Salimbangon, Ashley Beathrese T.

AU - Saksena, Miti S.

AU - Shin, Amber A.

AU - Matthews, Julia

AU - Mendez, Wanni

AU - Sominsky, Levy

AU - Mulder, Lubbertus C.F.

AU - Mendu, Rao

AU - Mouhieddine, Tarek H.

AU - Wang, Bo

AU - Chari, Ajai

AU - Cordon-Cardo, Carlos

AU - Krammer, Florian

AU - Jagannath, Sundar

AU - Simon, Viviana

AU - Wajnberg, Ania

AU - Parekh, Samir

N1 - Funding Information: Samir Parekh is supported by the National Cancer Institute (NCI) ( R01 CA244899 , CA252222 ) and receives research funding from Amgen , Bristol Myers Squibb (Celgene), and Karyopharm . This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) (contract 75N93019C00051 ), NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) (contracts HHSN272201400008C and HHSN272201400006C ), and NIAID grants U01AI141990 and U01AI150747 ; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute , National Institutes of Health , under Contract No. 75N91019D00024 , Task Order No. 75N91020F00003 . The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. We would like to thank the study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. We would like to acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai for their help. Funding Information: Samir Parekh is supported by the National Cancer Institute (NCI) (R01 CA244899, CA252222) and receives research funding from Amgen, Bristol Myers Squibb (Celgene), and Karyopharm. This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) (contract 75N93019C00051), NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) (contracts HHSN272201400008C and HHSN272201400006C), and NIAID grants U01AI141990 and U01AI150747; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 [5384]); and by anonymous donors. This effort was supported by the Serological Sciences Network (SeroNet) in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. We would like to thank the study participants for their generosity and willingness to participate in longitudinal COVID-19 research studies. We would like to acknowledge the clinical and research staff at the Center of Excellence for Multiple Myeloma at Mount Sinai for their help. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, and these list Florian Krammer as co-inventor. Viviana Simon and Carlos Cordon-Cardo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports consulting fees for Sanofi Genzyme. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. Other authors report no relevant conflicts of interest. Funding Information: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, and these list Florian Krammer as co-inventor. Viviana Simon and Carlos Cordon-Cardo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Bo Wang reports consulting fees for Sanofi Genzyme. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. Other authors report no relevant conflicts of interest.

PY - 2021/8/9

Y1 - 2021/8/9

KW - COVID-19

KW - SARS-CoV-2

KW - hematology

KW - multiple myeloma

KW - oncology

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85109712775&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2021.06.014

DO - 10.1016/j.ccell.2021.06.014

M3 - Letter

C2 - 34242572

AN - SCOPUS:85109712775

SN - 1535-6108

VL - 39

SP - 1028

EP - 1030

JO - Cancer Cell

JF - Cancer Cell

IS - 8

ER -